Immuron Limited's record sales of Travelan

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has reported record sales of Travelan, an over-the-counter immune supplement targeting pathogenic bacteria and their toxins in the gastrointestinal tract. The unaudited sales figures for FYTD Mar 2024 show a significant increase in sales, with Australia and the USA both experiencing substantial growth.

Executive Commentary on Sales Growth

Flavio Palumbo, Chief Commercial Officer, expressed excitement about the strong sales results of Travelan, particularly in Australia. He highlighted the company's investment in driving awareness of the Travelan brand, which has contributed to the continued strong sales results. Palumbo also expressed optimism about the potential for similar growth in North America as the company increases its investment and distribution during the upcoming vacation peak period.

Summary of Immuron's Travelan Sales Announcement

Immuron Limited (ASX: $IMC) has achieved record sales of Travelan, an over-the-counter immune supplement, with significant growth in both Australia and the USA. The sales figures for FYTD Mar 2024 indicate a 154% increase globally, with Australia experiencing a 234% increase and the USA a 35% increase. The company's Chief Commercial Officer, Flavio Palumbo, expressed excitement about the strong sales results and highlighted the company's investment in driving awareness of the Travelan brand. Immuron has also commenced Travelan sales in the USA through Walmart.com. The company's Travelan product is designed to prophylactically reduce the likelihood of contracting travelers' diarrhea, targeting pathogenic bacteria and their toxins in the gastrointestinal tract. Looking ahead, Immuron aims to capitalize on the strong sales momentum and expand its distribution in North America during the upcoming vacation peak period.